Cabaletta Bio, Inc. Net Debt
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
| Net Debt | ($1,000.0) | ($33.0M) | ($136.2M) | ($108.7M) | ($122.2M) | ($99.2M) | ($236.2M) |
Cabaletta Bio, Inc. (CABA) Net Debt comparison analysis
General
LTM Net Debt
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
CABA key stats
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.1 | 0.4 | 0.7 | 3.7 | 1.4 |
% margin | 0.0 0.0% | 0.0 0.0% | (0.1) 0.0% | (0.4) 0.0% | (0.7) 0.0% | (3.7) 0.0% | (1.4) 0.0% |
| Operating Expenses | 0.3 | 6.2 | 18.7 | 33.8 | 46.3 | 54.1 | 74.7 |
| Research & Development Expenses (R&D) | 0.0 | 4.5 | 11.7 | 21.4 | 32.5 | 39.3 | 55.4 |
| Selling, General & Administrative Expenses (SG&A) | 0.3 | 1.7 | 7.0 | 12.5 | 13.8 | 14.8 | 19.2 |
% margin | (0.3) 0.0% | (6.2) 0.0% | (18.7) 0.0% | (33.8) 0.0% | (46.3) 0.0% | (54.1) 0.0% | (74.7) 0.0% |
| Interest Income | 0.0 | 0.2 | 1.7 | 0.5 | 0.0 | 1.2 | 7.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | (0.3) | (12.2) | (16.9) | (33.3) | (46.3) | (53.0) | (67.7) |
% effective tax rate | (0.3) 133.3% | (0.2) 1.9% | (1.8) 10.9% | (0.8) 2.5% | (0.8) 1.6% | (1.2) 2.2% | 0.0 0.0% |
% margin | (0.3) 0.0% | (12.2) 0.0% | (15.1) 0.0% | (32.5) 0.0% | (45.5) 0.0% | (51.8) 0.0% | (67.7) 0.0% |
| EPS | (0.01) | (0.84) | (0.63) | (1.40) | (1.77) | (1.77) | (1.65) |
| Diluted EPS | (0.01) | (0.84) | (0.63) | (1.40) | (1.77) | (1.77) | (1.65) |
% margin | 0.1 0.0% | (6.0) 0.0% | (18.7) 0.0% | (33.5) 0.0% | (45.6) 0.0% | (53.0) 0.0% | (73.2) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Cabaletta Bio, Inc.'s Net Debt?
As of today, Cabaletta Bio, Inc.'s last 12-month Net Debt is ($167.8M), based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Cabaletta Bio, Inc.'s Net Debt growth rate?
Over the last year, Cabaletta Bio, Inc.'s Net Debt growth was 6.5%. The average annual Net Debt growth rates for Cabaletta Bio, Inc. have been 18.0% over the past three years, 18.8% over the past five years.
3) Is Cabaletta Bio, Inc.'s Net Debt growth rate Good?
Over the last year, Cabaletta Bio, Inc.'s Net Debt growth was 6.5%, which is higher than industry growth of (0.1%). It indicates that Cabaletta Bio, Inc.'s Net Debt growth is Bad.